Abstract:Abstract This study is aimed to identify serum biomarkers that predict treatment response and survival by screening proximity ligation assay (PLA) and verified enzyme-linked immunosorbent assay (ELISA) for patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy. One hundred and three patients with ESCC receiving CCRT consisting of taxane-/5-fluorouracil-based chemotherapy and 40Gy radiotherapy followed by surgery were prospectively enrolled. Serum samples were collected before and within 1 month after completion of CCRT. With the use of PLA, 15 biomarkers were simultaneously analyzed in the initial 79 patients. The biomarkers significantly associated with pathological response (PathR)/survival were verified by ELISA in an expanded group of 103 patients. Associations between serum levels of biomarkers and clinical factors correlating with PathR, disease-free survival (DFS), and overall survival (OS) were evaluated by ANOVA and log-rank tests. Following CCRT, 38 patients had pathologically complete response (37%), 44 microscopic (43%), and 21 macroscopic residual disease (20%). With a median follow-up of 66 months, the median DFS and OS were 23.7 months and 43.5 months, respectively. Among the 15 biomarkers screened by PLA, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1) were significantly associated with PathR and/or DFS. These biomarkers were further analyzed by ELISA to confirm initial biomarker findings by PLA. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR (p=0.042 and 0.019, respectively). Patients with high pre-CCRT VEGF-A/TGF-β1 levels (≥median) had significantly worse median DFS (9.3 months vs. 34.6 months, p=0.007) and worse median OS (26.7 months vs. 51.5 months, p=0.05). On multivariate analysis, PathR (p=0.001) and pre-CCRT high levels (≥median) of both VEGF-A and TGF-β1 (p=0.005) were independent factors for DFS. PathR (p=0.002) was the only significant factor for OS, while pre-CCRT high levels of both VEGF-A and TGF-β1 were borderline significant (p=0.065). In conclusion, serum VEGF-A may be used to predict post-CCRT pathological response. High serum levels of VEGF-A and TGF-β1 before CCRT associate with significantly worse DFS and a trend toward worse OS. Citation Format: Jason Chia-Hsien Cheng, Yun Chiang, Feng-Ming Hsu, Chiao-Ling Tsai, Chih-Hung Hsu, Jang-Ming Lee. Serum biomarkers of VEGF-A and TGF-β1 predict pathological response and survival of esophageal cancer patients treated with neoadjuvant chemoradiotherapy and esophagectomy. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A002.

AEG-1 promotes angiogenesis and may be a novel treatment target for tongue squamous cell carcinoma

Effect of transcatheter arterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor in cervical squamous cell carcinoma

Study on the Effects of Overexpression of Exogenous Notch1 in Tongue Squamous Cell Carcinoma Cells on Cell Growth and Expression of Epidermal Growth Factor Receptor in Vitro

Clinical significance and effect of AEG-1 on the proliferation, invasion, and migration of NSCLC: a study based on immunohistochemistry, TCGA, bioinformatics, in vitro and in vivo verification

Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma

Downregulation of Notch1 and Its Potential Correlation with Epidermal Growth Factor Receptor Signalling in Tongue Squamous Cell Carcinoma

[Cross-Talk Between Notch1 and Epidermal Growth Factor Receptor Signalling in Regulating Cell Proliferation of Human Tongue Squamous Carcinoma Cells].

Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond

Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis

[Expression of Notch1 and Epidermal Growth Factor Receptor in Human Tongue Squamous Cell Carcinoma and Precancerous Lesion].

Astrocyte Elevated Gene‐1 Interacts with Β‐catenin and Increases Migration and Invasion of Colorectal Carcinoma

AEG-1 promotes metastasis of breast cancer MCF-7 cells

Mrna-Seq-based Analysis Predicts: AEG-1 is a Therapeutic Target and Immunotherapy Biomarker for Pan-Cancer, Including OSCC

Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1

All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma

Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor

AEG-1 as a Novel Therapeutic Target in Colon Cancer: A Study from Silencing AEG-1 in BALB/c Mice to Large Data Analysis

Knockdown of Astrocyte Elevated Gene-1 Inhibits Tumor Growth and Modifies Micrornas Expression Profiles in Human Colorectal Cancer Cells.

Astrocyte Elevated Gene-1 As A Novel Clinicopathological And Prognostic Biomarker For Gastrointestinal Cancers: A Meta-Analysis With 2999 Patients

Abstract A002: Serum Biomarkers of VEGF-A and TGF-β1 Predict Pathological Response and Survival of Esophageal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy and Esophagectomy

Astrocyte Elevated Gene-1 is Associated with Metastasis in Head and Neck Squamous Cell Carcinoma Through P65 Phosphorylation and Upregulation of MMP1